Michael E. Luggen
0000-0002-1945-0103
Publication & Citation Trends
Publications
52 total
A Phase 3 Trial of Brepocitinib in Dermatomyositis
Cited by 0
Semantic Scholar
The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial
Cited by 0
Semantic Scholar
Diagnostic Utility of Antibodies to Extractable Nuclear Antigens in the Absence of Positive Antinuclear Antibodies
Cited by 0
Semantic Scholar
Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
Cited by 12
Semantic Scholar
POS1071 THE IMPACT OF COMORBIDITIES ON THE EFFICACY OF IL-6 INHIBITOR OLOKIZUMAB COMPARED TO ADALIMUMAB OA
Cited by 0
Semantic Scholar
Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus OA
Cited by 15
Semantic Scholar
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study OA
Cited by 34
Semantic Scholar
POS0645 LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4 OA
Cited by 1
Semantic Scholar
Research Topics
Rheumatoid Arthritis Research and Therapies
(32)
Systemic Lupus Erythematosus Research
(18)
Spondyloarthritis Studies and Treatments
(16)
Autoimmune and Inflammatory Disorders Research
(10)
Psoriasis: Treatment and Pathogenesis
(7)
Affiliations
Dartmouth College
Cincinnati Children's Hospital Medical Center
Bristol-Myers Squibb (Germany)
National Institute for Occupational Safety and Health
University of Utah